PRA Health Sciences Inc. (NASDAQ:PRAH) shares reached a new 52-week high on Monday . The company traded as high as $51.99 and last traded at $51.85, with a volume of 832,405 shares trading hands. The stock had previously closed at $49.25.

PRAH has been the topic of a number of analyst reports. Jefferies Group reiterated a “buy” rating and set a $57.00 price objective on shares of PRA Health Sciences in a research report on Friday, July 29th. First Analysis initiated coverage on shares of PRA Health Sciences in a research report on Monday, June 20th. They set an “equal weight” rating and a $47.00 price objective on the stock. Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 29th. KeyCorp reiterated a “hold” rating on shares of PRA Health Sciences in a research report on Sunday, May 22nd. Finally, Credit Suisse Group AG initiated coverage on shares of PRA Health Sciences in a research report on Monday, June 20th. They set a “neutral” rating and a $43.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $48.94.

The stock’s 50 day moving average price is $45.13 and its 200 day moving average price is $44.48. The company has a market capitalization of $3.15 billion and a PE ratio of 44.27.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Thursday, July 28th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $394.20 million for the quarter, compared to analysts’ expectations of $381.25 million. During the same quarter last year, the business earned $0.47 EPS. The company’s quarterly revenue was up 16.0% on a year-over-year basis. On average, equities research analysts predict that PRA Health Sciences Inc. will post $2.46 EPS for the current fiscal year.

In other PRA Health Sciences news, VP David W. Dockhorn sold 107,257 shares of the firm’s stock in a transaction on Friday, August 12th. The stock was sold at an average price of $49.00, for a total value of $5,255,593.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in PRA Health Sciences stock. Cornerstone Capital Management Holdings LLC. acquired a new position in shares of PRA Health Sciences Inc. (NASDAQ:PRAH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 29,727 shares of the company’s stock, valued at approximately $1,346,000.

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.